Biogen tau drug slows Alzheimer's decline 38 percent at two years
Life Sciences
Tuesday, November 17, 2026
- Updated Nov 17, 2026 20:46
Biogen's experimental tau drug diranersen slowed clinical decline in early Alzheimer's disease by 38 percent at two years on its lowest dose, up from 26 percent at 18 months, in Phase 2 data presented at the CTAD conference in Boston on Tuesday.
Why it matters: The readout is the first evidence that lowering tau can slow Alzheimer's progression, and Biogen is discussing the design of a Phase 3 trial with regulators, though a definitive result remains years away.
Data as of Ionis Pharmaceuticals announcement of November 17, 2026 (diranersen is developed by Ionis with Biogen) and Reuters reporting of the same presentation, both read in full in this run; the Endpoints News item that surfaced the data is paywalled and was not used. The two-year figures come from the open-label extension of the Phase 2 CELIA study, where the comparison group had received no doses or a single dose after moving into the extension. Developing item.
Biogen’s diranersen, an antisense therapy developed with Ionis Pharmaceuticals that silences the gene producing tau protein, slowed clinical decline by 38 percent at two years (Week 96) on the Clinical Dementia Rating, Sum of Boxes scale in the Phase 2 CELIA study of early Alzheimer’s disease, a 1.09 point treatment difference. The effect, at the 60 milligram twice-yearly spinal injection dose, grew from the 26 percent slowing reported at 18 months, with greater slowing across five of six measures of cognition, function and disease progression than at the earlier readout.
The two-year analysis comes from the study’s open-label extension, in which the comparison group had received no doses or a single dose of the drug, and higher doses produced weaker results at 18 months, slowing decline by 9 to 14 percent. Biogen said it is discussing the outline of a Phase 3 trial with regulators, with results still several years away.
Sources
- Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer's disease - Ionis Pharmaceuticals - 2026-11-17
- Biogen's anti-tau Alzheimer's drug benefits increase at 2 years - Reuters - 2026-11-17